id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-318457-k5kkd5qp	Yoganathan, Anusha	Cardiovascular disease and the impact of COVID‐19	2020-06-16		.txt	text/plain	251	22	48	key: cord-318457-k5kkd5qp cord_uid: k5kkd5qp It is, by now, well established that patients with pre-existing cardiovascular diseases, such as hypertension or ischemic heart disease, are more vulnerable and at risk from severe complications due to COVID-19. One of the most important pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is lying in its affinity to renin-angiotensin-aldosterone system (RAAS) through angiotensin converting enzyme inhibitor (ACEi) or utilization of angiotensin receptor blockers (ARBs). Several studies have reported equivocal outcomes in using ACEi and ARBs in patients with COVID-19, whether they were using ACEi/ARBs before contracting COVID-19 or they were initiated/suspended during the course of the infection; yet there is lack of robust evidence supporting the use or discontinuation of RAAS medications. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19	./cache/cord-318457-k5kkd5qp.txt	./txt/cord-318457-k5kkd5qp.txt